Publications by authors named "Y Ohi"

A retrospective study and an animal study were conducted to investigate factors affecting the transdermal fentanyl dose to achieve adequate pain relief in patients switched from other opioids. In the retrospective study, patient factors were included as gender, age, body mass index (BMI), and serum albumin concentration. In obese (BMI ≥25) patients, the post-titration dose of transdermal fentanyl was significantly lower than in normal (BMI 18.

View Article and Find Full Text PDF
Article Synopsis
  • A 60's female patient diagnosed with a left-sided breast mass underwent a core needle biopsy, revealing a round cell tumor with specific positive markers (vimentin, NKX2.2, BCOR, CD99) but no Ewing sarcoma fusion genes.
  • Following chemotherapy and total mastectomy, tissue analysis showed tumor cells with high nuclear-to-cytoplasmic ratios, leading to an integrative diagnosis of a malignant phyllodes tumor (PT) with extensive sarcomatous overgrowth.
  • The case highlights the significance of precise diagnosis and genomic profiling of rare breast tumors, emphasizing the differences in treatment strategies and prognoses between malignant PT and primary breast sarcomas (PBS).
View Article and Find Full Text PDF

Introduction: Cancer genome analysis using next-generation sequencing requires adequate and high-quality DNA samples. Genomic analyses were conventionally performed using formalin-fixed paraffin-embedded sections rather than cytology samples such as cell block or smear specimens. Specimens collected from liquid-based cytology (LBC) have the potential to be sources of high-quality DNA suitable for genetic analysis even after long-term storage.

View Article and Find Full Text PDF

Background: HER2-low breast cancer (BC) is a newly defined subset of HER2-negative BC. However, it is still uncertain whether HER2-low BC can be categorized as a distinct biological/clinical subgroup with any prognostic significance.

Methods: Invasive BC cases (n = 10,215) with Stage I-III were retrospectively analyzed to determine the HER2 status.

View Article and Find Full Text PDF

Background: Invasive lobular carcinoma (ILC) is distinct from invasive ductal carcinoma (IDC) in terms of their hormonal microenvironments that may require different therapeutic strategies. We previously reported that selective estrogen receptor modulator (SERM) function requires F-box protein 22 (Fbxo22). Here, we investigated the role of Fbxo22 as a potential biomarker contributing to the resistance to endocrine therapy in ILC.

View Article and Find Full Text PDF